Pacific Biosciences of Ca... (PACB)
Pacific Biosciences of California Statistics
Share Statistics
Pacific Biosciences of California has 273.86M shares outstanding. The number of shares has increased by 9.36% in one year.
| Shares Outstanding | 273.86M |
| Shares Change (YoY) | 9.36% |
| Shares Change (QoQ) | 8.76% |
| Owned by Institutions (%) | 94.58% |
| Shares Floating | 262.18M |
| Failed to Deliver (FTD) Shares | 438.18K |
| FTD / Avg. Volume | 3.88% |
Short Selling Information
The latest short interest is 60.54M, so 22.11% of the outstanding shares have been sold short.
| Short Interest | 60.54M |
| Short % of Shares Out | 22.11% |
| Short % of Float | 25.03% |
| Short Ratio (days to cover) | 6.95 |
Valuation Ratios
The PE ratio is -1.62 and the forward PE ratio is -2.5. Pacific Biosciences of California's PEG ratio is 0.25.
| PE Ratio | -1.62 |
| Forward PE | -2.5 |
| PS Ratio | 3.26 |
| Forward PS | 1.2 |
| PB Ratio | 0.99 |
| P/FCF Ratio | -2.37 |
| PEG Ratio | 0.25 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Pacific Biosciences of California.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.48, with a Debt / Equity ratio of 1.33.
| Current Ratio | 7.48 |
| Quick Ratio | 6.59 |
| Debt / Equity | 1.33 |
| Debt / EBITDA | -1.89 |
| Debt / FCF | -3.17 |
| Interest Coverage | -26.57 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $267.85K |
| Profits Per Employee | $-538.87K |
| Employee Count | 575 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.99 |
Taxes
| Income Tax | 316K |
| Effective Tax Rate | -0.1% |
Stock Price Statistics
The stock price has increased by -56.76% in the last 52 weeks. The beta is 2.03, so Pacific Biosciences of California's price volatility has been higher than the market average.
| Beta | 2.03 |
| 52-Week Price Change | -56.76% |
| 50-Day Moving Average | 1.4 |
| 200-Day Moving Average | 1.69 |
| Relative Strength Index (RSI) | 57.07 |
| Average Volume (20 Days) | 11.3M |
Income Statement
In the last 12 months, Pacific Biosciences of California had revenue of 154.01M and earned -309.85M in profits. Earnings per share was -1.13.
| Revenue | 154.01M |
| Gross Profit | 37.28M |
| Operating Income | -356.38M |
| Net Income | -309.85M |
| EBITDA | -356.38M |
| EBIT | -296.12M |
| Earnings Per Share (EPS) | -1.13 |
Balance Sheet
The company has 55.37M in cash and 672.43M in debt, giving a net cash position of -617.06M.
| Cash & Cash Equivalents | 55.37M |
| Total Debt | 672.43M |
| Net Cash | -617.06M |
| Retained Earnings | -2.15B |
| Total Assets | 1.26B |
| Working Capital | 429.38M |
Cash Flow
In the last 12 months, operating cash flow was -206.06M and capital expenditures -6.19M, giving a free cash flow of -212.25M.
| Operating Cash Flow | -206.06M |
| Capital Expenditures | -6.19M |
| Free Cash Flow | -212.25M |
| FCF Per Share | -0.77 |
Margins
Gross margin is 24.21%, with operating and profit margins of -231.4% and -201.18%.
| Gross Margin | 24.21% |
| Operating Margin | -231.4% |
| Pretax Margin | -200.98% |
| Profit Margin | -201.18% |
| EBITDA Margin | -231.4% |
| EBIT Margin | -231.4% |
| FCF Margin | -137.81% |
Dividends & Yields
PACB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for PACB is $2, which is 38.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $2 |
| Price Target Difference | 38.9% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | -0.32 |
| Piotroski F-Score | 3 |